Mantle cell lymphomaNews & Research
14 curated articles for Mantle cell lymphoma — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Leukemia Apr 22, 2026
PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis.
Protein arginine methyltransferase 5 (PRMT5) is overexpressed in B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). While PRMT5 is known to regulate multiple oncogenic pathways, including PI3K-AKT signaling, its role in lipid metabolism and ferroptosis,...
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
- Transplantation and cellular therapy Apr 19, 2026
Austrian real-world experience with standard of care brexucabtagene autoleucel in patients with relapsed or refractory mantle-cell lymphoma.
Mantle-cell lymphoma (MCL) represents a rare B-cell malignancy with a challenging treatment situation in the case of relapsed or refractory (r/r) disease. Brexu-cel as first approved chimeric antigen receptor T-cell (CART) therapy revolutionized the therapeutic landscape and outcome in r/r MCL patie...
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
- Cancer Apr 9, 2026
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.
The Bridging the Gaps (BTG) in Leukemia, Lymphoma and Multiple Myeloma Consensus Conference 2025 brought together a multidisciplinary group of oncology experts to address the complexities of lymphoma management, focusing on mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and diffuse ...
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
- Transplantation and cellular therapy Apr 8, 2026
Understanding Hodgkin and B-Cell Non-Hodgkin Lymphoma Progression in Patients Awaiting Autologous Transplant in a Resource-Constrained Setting.
Wait times for autologous hematopoietic cell transplantation (auto-HCT) are often prolonged in resource-constrained countries due to logistical and social limitations. In chemosensitive lymphomas, such delays may lead to disease progression or relapse. However, data on the impact of these delays on ...
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
- Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract Mar 21, 2026
Gastrointestinal mantle cell lymphoma.
Gastrointestinal mantle cell lymphoma.
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
- Blood Mar 19, 2026
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.
Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL) based on the ZUMA-2 cohort 1 (ClinicalTrials.gov identifier: NCT02601313) study in which brexu-cel demonstrate...
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
- Leukemia & lymphoma Mar 17, 2026
Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.
Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin B-cell lymphoma that presents significant clinical management challenges. Recent advancements in treatment strategies, such as Bruton's tyrosine kinase inhibitors (BTKi), chimeric antigen receptor T-cell (CAR-T) therapy, and ...
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
- Blood advances Mar 6, 2026
Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.
Patients with TP53 mutant mantle cell lymphoma (MCL) face poor chemotherapy response and early progression, requiring novel therapies. Nicotinamide phosphoribosyl transferase (NAMPT), the rate-limiting nicotinamide adenine dinucleotide salvage enzyme overexpressed in MCL cell lines and patient tissu...
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
- Expert review of hematology Mar 6, 2026
Approaches to the management of relapsed/refractory mantle cell lymphoma: navigating an increasingly complex therapeutic landscape.
Mantle cell lymphoma (MCL) represents a distinct subtype of mature B-cell lymphoma, considered incurable with a pattern of recurrent relapses and suboptimal responses to subsequent therapies that portend poorer prognosis with each recrudescent disease. Covalent and non-covalent Bruton tyrosine kinas...
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
- Blood advances Mar 5, 2026
Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma.
This real-world retrospective cohort study evaluated utilization and comparative effectiveness of covalent Bruton tyrosine kinase inhibitor (cBTKi) monotherapies in relapsed/refractory mantle cell lymphoma (R/R MCL) from electronic health records in the United States. Adults with R/R MCL who receive...
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
- Blood advances Feb 17, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.
The benefit of rituximab maintenance after first-line (1L) bendamustine-rituximab (BR) in patients with mantle cell lymphoma (MCL) remains uncertain, with inconsistent results from the phase 2 MAINTAIN trial and several retrospective studies. We conducted a large retrospective study at 27 US and Can...
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
- Blood advances Feb 13, 2026
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.
The pivotal ZUMA-2 trial evaluated the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (brexu-cel) for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL), and ultimately led to the approval of brexu-cel for R/R MCL. Here we report a retrospective analysis ...
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
- Blood advances Feb 13, 2026
Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.
Relmacabtagene autoleucel (relma-cel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, is approved in China for relapsed/refractory (R/R) large B-cell lymphoma and follicular lymphoma. This phase 2, open-label, single-arm, multicenter study evaluated its efficacy and safety in Chinese...
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
- Critical reviews in oncology/hematology Jan 24, 2026
Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis.
Chimeric antigen receptor (CAR) T-cell therapy, a form of adoptive immunotherapy, has expanded treatment options for various hematologic malignancies. However, CAR T therapy is associated with a range of side effects, including immune effector cell-associated neurotoxicity syndrome (ICANS), with var...
Why it matters: Recent peer-reviewed research on Mantle cell lymphoma that may be relevant for patients and caregivers.
More on Mantle cell lymphoma
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.